Clinical Trials
Closed
Phase
Accrual
14%
SWOG Clinical Trial Number
SWOG-8935
Evaluation of Continuous Infusion Interleukin-2 (IL-2) in Patients with Squamous Cell Carcinoma of the Head and Neck, Phase II
Activated
11-15-1990
Closed
06-15-1992
Closed
Phase
Accrual
46%
Published
SWOG Clinical Trial Number
SWOG-8730
Evaluation of Amonafide in Esophageal Cancer
Activated
11-01-1990
Closed
04-15-1992
Closed
Phase
Accrual
77%
Published
SWOG Clinical Trial Number
SWOG-8936
Evaluation of Piroxantrone in Gastric Carcinoma
Activated
11-01-1990
Closed
06-15-1992
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-9038
Extended Administration of Oral Etoposide and Cyclophosphamide for the Treatment of Advanced Non-Small Cell Lung Cancer
Activated
11-01-1990
Closed
07-01-1991
Closed
Phase
Accrual
77%
Published
SWOG Clinical Trial Number
SWOG-9006
A Phase II 19F Magnetic Resonance Spectroscopy (MRS) Study of 5-FU and Correlation with Clinical Results of 5-FU/Leucovorin (LV) Therapy in Patients with Carcinomas of the Gastrointestinal Tract
Research Committee(s)
Gastrointestinal Cancer
Activated
10-15-1990
Closed
11-01-1996
Closed
Phase
Accrual
63%
Published
SWOG Clinical Trial Number
SWOG-8956
Study of Cisplatin and 5-FU Infusion for Treatment of Advanced and/or Recurrent Metastatic Carcinoma of the Urinary Bladder
Research Committee(s)
Genitourinary Cancer
Activated
10-01-1990
Closed
06-15-1993
Closed
Phase
Accrual
39%
Published
SWOG Clinical Trial Number
SWOG-9028
A Phase III Randomized Trial of Combination Therapy for Multiple Myeloma Comparison of (1) VAD to VAD/ Quinine for Induction with Crossover to VAD/ Quinine for VAD Induction Failures; (2) Alpha-2b Interferon or Alpha-2b Interferon plus Prednisone for Remission Maintenance
Research Committee(s)
Myeloma
Activated
10-01-1990
Closed
05-15-1994
Closed
Phase
Published
SWOG Clinical Trial Number
SWOG-8855
Prognostic Value of Cytometry Measurements of Cellular DNA Parameters in Head and Neck Cancer Patients, Ancillary
Research Committee(s)
Head and Neck Cancer
Activated
09-15-1990
Closed
09-01-2002
Closed
Phase
Accrual
28%
Published
SWOG Clinical Trial Number
SWOG-8922
Phase I Trial of Doxorubicin, DTIC and Ifosfamide with Recombinant Granulocyte-Macrophage Colony Stimulating Factor in Advanced Soft Tissue Sarcomas
Research Committee(s)
Sarcoma
Activated
09-15-1990
Closed
09-15-1992
Closed
Phase
Accrual
40%
SWOG Clinical Trial Number
SWOG-8914
Standard Dose Carboplatin/Cyclophosphamide/GM-CSF vs. Intensive Carboplatin/Cyclophosphamide/GM-CSF Induction Therapy - Second-Look Cytoreductive Surgery - Followed by High Dose Day 1 and Day 8 IV Cisplatin for Patients with Stages III and IV Suboptimal Disease Ovarian Cancer
Activated
09-15-1990
Closed
06-15-1994
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8933
Evaluation of Piroxantrone in Pancreatic Adenocarcinoma
Activated
09-01-1990
Closed
09-15-1991
Closed
Phase
Accrual
76%
Published
SWOG Clinical Trial Number
SWOG-8945
Evaluation of Piroxantrone in Patients with Advanced Renal Cell Carcinoma
Activated
09-01-1990
Closed
05-01-1991
Closed
Phase
Accrual
5%
SWOG Clinical Trial Number
SWOG-8901
Closed
Phase
Accrual
100%
SWOG Clinical Trial Number
SWOG-9037 (CALGB-9196)
Prediction of Recurrence and Survival in Node-Negative Breast Cancer Patients Using a Panel of Prognostic Factors: A Companion Protocol to SWOG-8897 (EST-2188, CALGB-8897, INT-0102)
Research Committee(s)
Genitourinary Cancer
Activated
09-01-1990
Closed
05-15-1993
Closed
Phase
Accrual
100%
Published
SWOG Clinical Trial Number
SWOG-8797 (INT-0107) (GOG-109) (RTOG-91-12)
A Randomized Comparison of 5-FU Infusion and Bolus Cisplatin as an Adjunct to Radiation Therapy, Versus Radiation Therapy Alone in Selected Patients with Stages I-A2, I-B and II-A Carcinoma of the Cervix Following Radical Hysterectomy and Node Dissection
Research Committee(s)
Gynecologic Cancer
Activated
09-01-1990
Closed
12-15-1996
Closed
Phase
SWOG Clinical Trial Number
SWOG-8861
Evaluation of Quality of Life in Patients with Clinical Stage A2 or B Adenocarcinoma of the Prostate Enrolled on SWOG-8890 (Int-CR-87-017)
Activated
07-15-1990
Closed
01-01-1992
Closed
Phase
Accrual
72%
Published
SWOG Clinical Trial Number
SWOG-8911
Evaluation of Piroxantrone in Refractory Carcinoma of the Breast
Activated
07-01-1990
Closed
05-15-1993
Closed
Phase
Accrual
45%
Published
SWOG Clinical Trial Number
SWOG-8834
A Phase II Evaluation of Fazarabine in Central Nervous System Tumors
Research Committee(s)
Brain Cancer
Activated
07-01-1990
Closed
12-01-1991
Closed
Phase
Accrual
83%
Published
SWOG Clinical Trial Number
SWOG-8930
Phase II Trial of Piroxantrone for Advanced or Metastatic Soft-Tissue Sarcomas
Activated
06-15-1990
Closed
12-01-1991
Closed
Phase
Accrual
3%
SWOG Clinical Trial Number
SWOG-8821
Study of Continuous Infusion Recombinant Interleukin-2 (rIL-2) in Patients with Refractory Carcinoma of the Breast
Activated
05-15-1990
Closed
08-01-1991